Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
| Data | Nome del titolare | Azioni transazionate | Intervallo di valore ($) | Tipo di transazione | Intervallo di prezzo ($) | Azioni a fine dichiarazione | % di variazione |
|---|---|---|---|---|---|---|---|
| 2026-06-25 | Dr. Robert J. LechleiderChief Medical Officer | -55,00k | 611,51k | Derivative Exercise and Sale | 8,73 - 20,66 | 15,81k | - |
| 2026-06-15 | Mr. Max RosettCFO | -60,00k | 1,03M | Derivative Exercise and Sale | 1,05 - 18,23 | 54,04k | - |
| 2026-06-05 | Mr. Jean-Jacques BienaimeIndependent Director | -10,50k | 203,82k | Vendita | 19,41 - 19,44 | 43,42k | -19,48% |
| 2026-06-05 | Mr. Jean-Jacques BienaimeIndependent Director | 10,50k | 204,26k | Acquisto | 19,27 - 19,48 | 43,42k | 31,90% |
| 2026-05-15 | Mr. Jean-Jacques BienaimeIndependent Director | 5,00k | 103,50k | Acquisto | 20,70 | 43,42k | 13,02% |
| 2026-04-02 | Dr. Jack HigginsChief Scientific Officer | -9,44k | 204,24k | Automatic Disposition | 21,64 | 25,00k | -27,41% |
| 2026-04-02 | Mr. Max RosettCFO | -65,00k | 1,34M | Derivative Exercise and Sale | 1,05 - 22,48 | 54,04k | - |
| 2026-04-02 | Mr. Max RosettCFO | 6,56k | 6,89k | Derivative Exercise and Retained Stock | 1,05 | 54,04k | 13,82% |
| 2026-03-30 | Dr. Jack HigginsChief Scientific Officer | -6,29k | 0,00 | Other Disposition | - | 34,44k | -15,45% |
| 2026-03-27 | Dr. Clay B. SiegallChairman, President & CEO | 25,45k | 500,60k | Acquisto | 19,67 | 690,70k | 3,83% |
| 2026-03-20 | Mr. Philip WagenheimIndependent Director | -65,00k | 1,34M | Vendita | 20,47 - 20,65 | 341,15k | -16,00% |
| 2026-03-10 | Mr. Jean-Jacques BienaimeIndependent Director | 2,00k | 43,67k | Acquisto | 21,55 - 22,12 | 38,42k | 5,49% |
| 2025-12-30 | Dr. Clay B. SiegallChairman, President & CEO | 4,73k | 100,02k | Acquisto | 21,15 | 665,25k | 0,72% |
| 2025-12-22 | Arsenal Bridge Venture II, LLCSocietà | -11,25k | 251,35k | Vendita | 22,34 | 2,03M | -0,55% |
| 2025-12-22 | Arsenal Bridge Venture II, LLCSocietà | -371,95k | 8,08M | Automatic Disposition | 21,72 | 2,03M | -15,48% |
| 2025-12-19 | Dr. Jack HigginsChief Scientific Officer | -3,00k | 0,00 | Other Disposition | - | 40,73k | -6,86% |
| 2025-12-19 | Dr. Clay B. SiegallChairman, President & CEO | 7,28k | 149,05k | Acquisto | 20,48 | 660,53k | 1,11% |
| 2025-12-19 | Dr. Clay B. SiegallChairman, President & CEO | -200,00k | 0,00 | Other Disposition | - | 660,53k | -23,24% |
| 2025-12-19 | Dr. Philip TsaiChief Technical Officer | 10,00k | 204,90k | Acquisto | 20,49 | 43,30k | 30,03% |
| 2025-12-18 | Dr. Clay B. SiegallChairman, President & CEO | 46,51k | 999,99k | Acquisto | 21,50 | 853,25k | 5,77% |
| 2025-09-10 | Dr. Jack HigginsChief Scientific Officer | 22,00k | 29,70k | Derivative Exercise and Retained Stock | 1,35 | 40,73k | 117,46% |
Assistenza: support@advfn.it
Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni
Registrati con e-mail
Hai già un account? Accedi
Non hai un account? Registrati
Registrandomi, confermo di aver letto, capito, e accetto i termini e condizioni ADVFN e che sono un investitore privato.
Caratteristiche principali
Premium
